124I-AT-03

124I-AT-03 is an experimental amyloid-targeting radiopharmaceutical agent based on a fusion protein (AT-03) designed to bind and facilitate the removal of systemic amyloid deposits, including both AL (light chain) and ATTR (transthyretin) types. The drug has demonstrated high affinity for various human amyloid extracts and can promote macrophage-mediated phagocytosis of amyloid fibrils, facilitating clearance in preclinical models. 124I-AT-03 is a radiolabeled form of the AT-03 fusion protein, likely labeled with iodine-124 for use in imaging or therapeutic applications in amyloidosis. Development and preclinical work are performed by Attralus, a company specializing in diagnostics and therapeutics for systemic amyloidosis.

Other names

AT-03AT03AT 03